Skip to content
Menu

Barclays Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $160

Benzinga Newsdesk 4 hours ago

Analyst RatingsNewsPrice TargetHot

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Barclays analyst Emily Field maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and raises the price target from $145 to $160.

Barclays analyst Emily Field maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and raises the price target from $145 to $160.

Read at benzinga.com